Records containing: Lymphoma, Extranodal NK-T-Cell
This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.
Follow recorded terms in Drug Alerts for Android. Free includes unlimited local condition follows and an on-open recent-record watchlist. Plus adds no ads and personal organization tools.
All
FDA submission records
EMA medicine records
ClinicalTrials.gov record updates
ClinicalTrials.gov records with results posted
-
CLINICAL_TRIALS study record update · 2026-04-07Pembrolizumab and Radiotherapy for Previously Untreated Patients With Limited Stage NK/T Cell Lymphoma Who Are Not Eligible to Chemotherapy
-
CLINICAL_TRIALS study record update · 2024-08-27The Efficacy and Safety of Selinexor, Anti-PD-1 Antibody Plus Golidocitinib in the Treatment of Relapsed or Refractory Natural Killer / T-cell Lymphoma
-
CLINICAL_TRIALS study record update · 2022-08-18Allogeneic Stem Cell Transplantation With 3-days Busulfan Plus Fludarabine as Conditioning in Patients With Relapsed or Refractory T-, NK/T-cell Lymphomas
-
CLINICAL_TRIALS study record update · 2022-05-25Anti-CD30 CAR T Cells With Fully-human Binding Domains for Treating CD30-expressing Lymphomas Including Anaplastic Large Cell Lymphomas
-
CLINICAL_TRIALS study record update · 2022-03-31Spanish Academy of Dermatology and Venereology (AEDV) Registry of Primary Cutaneous Lymphoma
- Organize your saved records without ads with Plus.
-
CLINICAL_TRIALS study record update · 2021-09-24A Phase II Study of Avelumab in Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma
-
CLINICAL_TRIALS study record update · 2019-03-13A Phase 2 Single Arm Study to Investigate the Efficacy of Autologous EBV-specific T-cells for the Treatment of Patients With Aggressive EBV Positive Extranodal NK/T-cell Lymphoma (ENKTCL)
-
CLINICAL_TRIALS study record update · 2018-05-09Phase 2 Trial of Pegaspargase-Gemox Chemotherapy in Newly Diagnosed, Nasal Type, Extranodal Natural Killer/T-cell Lymphoma
-
CLINICAL_TRIALS study record update · 2018-05-09Comparison of Gemcitabine, Oxaliplatin and Pegaspargase and Etoposide, Vincristine, Doxorubicin, Cyclophosphamide and Prednisone as First-line Chemotherapy in Patients With NK/T-cell Lymphoma：a Prospective Randomized Phase III Study
-
CLINICAL_TRIALS study record update · 2017-11-08A Study of Gemcitabine, L- Asparaginase, Ifosfamide, Dexamethasone and Etoposide Chemotherapy Followed by ASCT for Newly Diagnosed Stage IV, Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma, Nasal Type
-
CLINICAL_TRIALS study record update · 2017-02-13Evaluating Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography / Computed Tomography With Liver SUVmax-based Criteria for Prognosis of Patients With NK/T-cell Lymphoma
-
CLINICAL_TRIALS study record update · 2017-02-1318F-FDG PET/CT-based Prognostic Model for Predicting Outcome in Patients With Natural Killer/T-cell Lymphoma
-
CLINICAL_TRIALS study record update · 2016-08-25Research About the Differences Between Chidamide Taken Daily and Twice a Week in Pharmacokinetics
-
CLINICAL_TRIALS study record update · 2016-04-20Combination of Gemcitabine, Oxaliplatin, and Asparaginase (GELOX) With Concurrent Involved-Field Radiation Therapy for Patients With Stage IE/IIE Extranodal Natural Killer/T-Cell Lymphoma:a Phase II Study
-
CLINICAL_TRIALS study record update · 2016-01-21Phase 2 Trial of Alemtuzumab and Dose-Adjusted Epoch in Chemotherapy Naive Aggressive T and NK-Cell Lymphomas
-
CLINICAL_TRIALS study record update · 2013-12-24Phase II Study of MESA Chemotherapy in Patients With Natural Killer/T Cell Lymphoma